Melika Davis, Senior VP and Global Head of Clinical Operations, joined our Cancer Has No Borders podcast to share insights on our innovative approach to managing clinical trials.

We were honored to take part in our very first panel at SXSW! Mark Lanasa, Pat Garcia-Gonzalez, and Jeff Allen shared powerful insights on how global collaboration can transform access to cancer care. Check out this clip for a glimpse into this important and inspiring conversation.

#News for #Investors and #Media: We're proud to share that our therapy has been officially reimbursed by the Belgian National Institute for Health and Disability Insurance for the treatment of second-line oesophageal squamous cell carcinoma (ESCC). This significant milestone

Thrilled to welcome Kris Stubbs as the new leader of our team in Canada! With his extensive experience in oncology, Kris will be instrumental in driving our mission forward—bringing innovative cancer treatments to those who need them most. #Oncology #Innovation #Leadership

I’m honored to be named to the The Medicine Maker 2025 Power list in the Biopharmaceutical category. This recognition is a reflection of the incredible journey our team has been on. Fifteen years ago, I imagined a future where our work would make a meaningful difference—and today,

Welcome Marcello Damiani! Marcello's expertise and vision will be a key part of our journey as we drive digital innovation to new heights. We look forward to the impact he will make as part of our growing team.

Today, we announced our Q1 2025 earnings, marking a significant milestone for the company – our first quarter of GAAP profitability. I'm incredibly proud of our team's hard work and dedication to reaching this achievement.

In the latest episode of Cancer Has No Borders Podcast, we had the pleasure of speaking with Meghan Gutierrez, CEO of the Lymphoma Research Foundation. In her interview she covered the foundation’s vital work in addressing unmet needs in lymphoma care, advancing clinical trials, and supporting

We’re proud to announce our new name—BeOne Medicines—and our redomiciliation to Switzerland are now officially in effect. This marks a major milestone in our evolution as a company. BeOne is more than just a name change. It reflects who we are today as a leading global oncology

As #ASCO2025 comes to a close, I’m incredibly proud of what Team BeOne accomplished on the ground in Chicago. We were honored to unveil new clinical data that reflects the strength and depth of our growing pipeline—both in breast cancer and hematologic malignancies. On the

This year, we’re showcasing more data than ever before, with 31 abstracts across seven disease areas – all highlighting the progress of our hematology clinical development program and our commitment to targeted therapies that raise the standard of care. I look forward to

Following BeOne’s recent redomiciliation to Switzerland, it was an honor to meet with State Secretary for Economic Affairs Helene Budliger Artieda, alongside our Board Member Anthony Hooper, Head of Government Affairs Michael Schoen, and members of our Swiss Affiliate team. This

Thank you, Ernst & Young for this incredible honor. As I reflect on the past 15 years and my journey as an entrepreneur, I’m humbled by the remarkable milestones and achievements made by our team. As we take the next step in our new chapter towards becoming a diversified biotech

I enjoyed my conversation with Yaron last week, where we explored how our unique culture—grounded in ownership and urgency—truly sets us apart. Full interview below.

In the latest episode of Cancer Has No Borders, we’re joined by Matthew Shaulis, General Manager for North America at BeOne Medicines. Matt brings a deeply personal connection to our mission -- one that shapes how he leads and why he’s so passionate about changing the cancer

Each year in the U.S., nearly 2 million people are diagnosed with cancer. Globally, it’s the second leading cause of death—and by 2040, cases are projected to surge to 30 million, with more than 15 million deaths. At BeOne, we’re confronting this staggering challenge head-on.

At BeOne Medicines, we’re building a future where innovation in oncology is accessible to every patient, everywhere. Cancer impacts millions globally, yet the most advanced treatments often remain out of reach for far too many. We’re here to change that. From conducting

Today, we announced our Q2 2025 earnings, continuing to build on the momentum from earlier this year. This quarter marked another strong performance for the company, driven by the dedication and innovation of our BeOne Medicines team. I’m proud of the consistent progress we’re

New Epidsode: Cancer Has No Borders Podcast: Why is cancer mortality nearly 50% higher in parts of Eastern Europe than in Western Europe? In our latest podcast episode, we tackle this urgent and deeply personal question—with real talk, real data, and real solutions. - What’s

At BeOne Medicines, we are committed to advancing science for patients facing some of the most difficult cancers. Today we announced positive topline results from our Phase 2 study of our next-generation BCL2 inhibitor in relapsed/refractory mantle cell lymphoma. This milestone